Author + information
- Received November 11, 2017
- Revision received February 12, 2018
- Accepted February 15, 2018
- Published online April 9, 2018.
- Arantxa González, PhDa,b,
- Erik B. Schelbert, MD, MSc,
- Javier Díez, MD, PhDa,b,d,∗ ( and )
- Javed Butler, MD, MPH, MBAe,∗∗ ()
- aProgram of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain
- bCIBERCV (Centro de Investigación Biomédica en Red Enfermedades Cardiovasculares), Carlos III Institute of Health, Madrid, Spain
- cDepartment of Medicine, Heart and Vascular Institute, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
- dDepartment of Cardiology and Cardiac Surgery, University of Navarra Clinic, Pamplona, Spain
- eDepartment of Medicine, University of Mississippi, Jackson Mississippi
- ↵∗Address for correspondence:
Dr. Javier Díez, Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Av. Pío XII 55, 31008 Pamplona, Spain.
- ↵∗∗Dr. Javed Butler, University of Mississippi Medical Center, Department of Medicine (L650), 2500 N. State Street, Jackson, Mississippi 39216.
Myocardial interstitial fibrosis contributes to left ventricular dysfunction leading to the development of heart failure. Basic research has provided abundant evidence for the cellular and molecular mechanisms behind this lesion and the pathways by which it imparts a detrimental impact on cardiac function. Translation of this knowledge, however, to improved diagnostics and therapeutics for patients with heart failure has not been as robust. This is partly related to the paucity of biomarkers to accurately identify myocardial interstitial fibrosis and to the lack of personalized antifibrotic strategies to treat it in an effective manner. This paper summarizes current knowledge of the mechanisms and detrimental consequences of myocardial interstitial fibrosis, discusses the potential of circulating and imaging biomarkers available to recognize different phenotypes of this lesion and track their clinical evolution, and reviews the currently available and potential future therapies that allow its individualized management in heart failure patients.
All authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received November 11, 2017.
- Revision received February 12, 2018.
- Accepted February 15, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.